Oncolytics Biotech Inc Cash Flow Conversion Efficiency
Oncolytics Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Oncolytics Biotech Inc (ONC) has a cash flow conversion efficiency ratio of -0.899x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.47 Million ≈ $-3.96 Million USD) by net assets (CA$6.09 Million ≈ $4.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oncolytics Biotech Inc (1999–2024)
Cash flow conversion efficiency of Oncolytics Biotech Inc from 1999 to 2024. This chart illustrates how Oncolytics Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Oncolytics Biotech Inc for real-time trading data and today's change.
Oncolytics Biotech Inc Cash Flow Conversion Ratio Explained
Oncolytics Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oncolytics Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncolytics Biotech Inc ranked by their cash flow conversion efficiency. Also see Oncolytics Biotech Inc (ONC) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seoul Broadcasting System
KO:034120
|
0.012x |
|
Power Nickel Inc
V:PNPN
|
-0.844x |
|
Oyak Yatirim Menkul Degerler AS
IS:OYYAT
|
-0.010x |
|
Nusantara Pelabuhan Handal Tbk PT
JK:PORT
|
0.114x |
|
UPDATER SERVICES LIMITED
NSE:UDS
|
0.032x |
|
Uttam Sugar Mills Limited
NSE:UTTAMSUGAR
|
0.747x |
|
Clarus Corp
NASDAQ:CLAR
|
0.009x |
|
Protara Therapeutics Inc
NASDAQ:TARA
|
-0.087x |
Annual Cash Flow Conversion Efficiency for Oncolytics Biotech Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Oncolytics Biotech Inc from 1999 to 2024. Review Oncolytics Biotech Inc (ONC) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$5.98 Million ≈ $4.33 Million |
CA$-26.97 Million ≈ $-19.51 Million |
-4.507x | -336.69% |
| 2023-12-31 | CA$27.56 Million ≈ $19.94 Million |
CA$-28.45 Million ≈ $-20.58 Million |
-1.032x | -17.12% |
| 2022-12-31 | CA$26.50 Million ≈ $19.17 Million |
CA$-23.36 Million ≈ $-16.89 Million |
-0.881x | -41.80% |
| 2021-12-31 | CA$36.10 Million ≈ $26.11 Million |
CA$-22.43 Million ≈ $-16.23 Million |
-0.621x | +30.29% |
| 2020-12-31 | CA$24.75 Million ≈ $17.91 Million |
CA$-22.07 Million ≈ $-15.96 Million |
-0.892x | -100.48% |
| 2019-12-31 | CA$-107.89K ≈ $-78.05K |
CA$-19.91 Million ≈ $-14.40 Million |
184.497x | +9688.95% |
| 2018-12-31 | CA$6.20 Million ≈ $4.48 Million |
CA$-11.92 Million ≈ $-8.62 Million |
-1.924x | -7.03% |
| 2017-12-31 | CA$8.28 Million ≈ $5.99 Million |
CA$-14.89 Million ≈ $-10.77 Million |
-1.798x | -54.00% |
| 2016-12-31 | CA$10.69 Million ≈ $7.73 Million |
CA$-12.48 Million ≈ $-9.03 Million |
-1.167x | -91.56% |
| 2015-12-31 | CA$24.67 Million ≈ $17.85 Million |
CA$-15.03 Million ≈ $-10.88 Million |
-0.609x | +57.21% |
| 2014-12-31 | CA$13.82 Million ≈ $10.00 Million |
CA$-19.68 Million ≈ $-14.23 Million |
-1.424x | -29.41% |
| 2013-12-31 | CA$22.21 Million ≈ $16.07 Million |
CA$-24.44 Million ≈ $-17.68 Million |
-1.100x | +52.51% |
| 2012-12-31 | CA$14.79 Million ≈ $10.70 Million |
CA$-34.26 Million ≈ $-24.78 Million |
-2.317x | -203.39% |
| 2011-12-31 | CA$29.52 Million ≈ $21.35 Million |
CA$-22.54 Million ≈ $-16.31 Million |
-0.764x | -77.55% |
| 2010-12-31 | CA$41.93 Million ≈ $30.33 Million |
CA$-18.03 Million ≈ $-13.05 Million |
-0.430x | +16.02% |
| 2009-12-31 | CA$32.84 Million ≈ $23.76 Million |
CA$-16.82 Million ≈ $-12.17 Million |
-0.512x | +68.33% |
| 2008-12-31 | CA$9.45 Million ≈ $6.84 Million |
CA$-15.29 Million ≈ $-11.06 Million |
-1.617x | -233.25% |
| 2007-12-31 | CA$27.96 Million ≈ $20.23 Million |
CA$-13.57 Million ≈ $-9.82 Million |
-0.485x | -22.97% |
| 2006-12-31 | CA$30.80 Million ≈ $22.28 Million |
CA$-12.16 Million ≈ $-8.79 Million |
-0.395x | -58.73% |
| 2005-12-31 | CA$44.45 Million ≈ $32.16 Million |
CA$-11.05 Million ≈ $-8.00 Million |
-0.249x | -3.47% |
| 2004-12-31 | CA$38.39 Million ≈ $27.77 Million |
CA$-9.22 Million ≈ $-6.67 Million |
-0.240x | -9.74% |
| 2003-12-31 | CA$25.02 Million ≈ $18.10 Million |
CA$-5.48 Million ≈ $-3.96 Million |
-0.219x | +50.03% |
| 2002-12-31 | CA$16.56 Million ≈ $11.98 Million |
CA$-7.26 Million ≈ $-5.25 Million |
-0.438x | -63.61% |
| 2001-12-31 | CA$15.95 Million ≈ $11.54 Million |
CA$-4.27 Million ≈ $-3.09 Million |
-0.268x | -68.90% |
| 2000-12-31 | CA$19.92 Million ≈ $14.41 Million |
CA$-3.16 Million ≈ $-2.28 Million |
-0.159x | -105.58% |
| 1999-12-31 | CA$6.93 Million ≈ $5.01 Million |
CA$-534.35K ≈ $-386.54K |
-0.077x | -- |
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more